Patents Assigned to SICHUAN JIUZHANG BIOLOGICAL SCIENCE AND TECHNOLOGY CO., LTD.
-
Patent number: 11628199Abstract: A medicine for combined use in cancer treatment, comprising chlorogenic acid and a hormone drug which have unit preparations of the same or different specifications and which are administered either together or separately, as well as comprising a pharmaceutically acceptable carrier. The combined use of the chlorogenic acid and hormone drug achieves the effects of synergistic interaction, which thus overcome the defects of single drug treatment, such as a major toxic side effect and a poor treatment outcome and may reverse the drug resistance to hormone drugs and has good prospects for clinical application.Type: GrantFiled: August 17, 2018Date of Patent: April 18, 2023Assignee: SICHUAN JIUZHANG BIOLOGICAL SCIENCE AND TECHNOLOGY CO., LTDInventors: Jie Zhang, Wang Huang, Huarong Yang
-
Patent number: 11596598Abstract: An anti-tumor composition for nasal administration has chlorogenic acid as an active ingredient, with the addition of pharmaceutically acceptable excipients or auxiliary ingredients. The chlorogenic acid preparation can improve the bioavailability of chlorogenic acid for nasal administration, penetrate the blood-brain barrier, have a significant inhibitory effect on brain tumors and nasopharyngeal carcinoma, and possess a clinical application value.Type: GrantFiled: October 1, 2020Date of Patent: March 7, 2023Assignee: SICHUAN JIUZHANG BIOLOGICAL SCIENCE AND TECHNOLOGY CO., LTD.Inventors: Jie Zhang, Wang Huang, Fei Zhang, Ya Zhang
-
Patent number: 11547715Abstract: A drug that contains chlorogenic acid is effective in treating chordoma. When administered to a patient in need thereof, chlorogenic acid can significantly inhibit the proliferation of chordoma cells, reduce the expression level of multi-drug resistance gene MDR1 of chordoma cells, reverse the multi-drug resistance of chordoma cells, and effectively treat chordoma disease.Type: GrantFiled: December 27, 2018Date of Patent: January 10, 2023Assignee: SICHUAN JIUZHANG BIOLOGICAL SCIENCE AND TECHNOLOGY CO., LTD.Inventors: Jie Zhang, Yazhuo Zhang, Mengtian Zhang
-
Patent number: 11376267Abstract: A drug combination for treatment of amyotrophic lateral sclerosis includes chlorogenic acid, vitamin E, vitamin C, coenzyme Q10, and creatine phosphate sodium, as well as pharmaceutically acceptable carriers, in which chlorogenic acid, vitamin E, vitamin C, coenzyme Q10, and creatine phosphate sodium are unit preparations having same or different specifications, that are simultaneously or separately administrated. The combination of chlorogenic acid, vitamin E, vitamin C, coenzyme Q10, and creatine phosphate sodium shows a synergistic effect on amyotrophic lateral sclerosis, thus provides a combination with excellent therapeutic effect on amyotrophic lateral sclerosis, which delays the progression of amyotrophic lateral sclerosis.Type: GrantFiled: June 28, 2019Date of Patent: July 5, 2022Assignee: SICHUAN JIUZHANG BIOLOGICAL SCIENCE AND TECHNOLOGY CO., LTD.Inventors: Jie Zhang, Xiaoguang Chen, Huarong Yang, Wenbin Li
-
Patent number: 11135160Abstract: Provided are a use of chlorogenic acid in preparing pharmaceuticals for the inhibition of LAG-3 and a use of chlorogenic acid in preparing pharmaceuticals for the treatment of LAG-3-mediated diseases. The inhibition of LAG-3 by chlorogenic acid is useful in cancer therapy, anti-viral therapy, and sepsis treatment. The oral bioavailability of chlorogenic acid is enhanced by preparing chlorogenic acid as a gastric floating tablet.Type: GrantFiled: February 20, 2017Date of Patent: October 5, 2021Assignee: SICHUAN JIUZHANG BIOLOGICAL SCIENCE AND TECHNOLOGY CO., LTDInventors: Jie Zhang, Xiaoguang Chen, Nina Xue, Mengtian Zhang
-
Patent number: 10314806Abstract: A preparation containing a chlorogenic acid crystal form. The crystal form is an orthorhombic crystal system, a space group is P212121, cell parameters are as follows: a=7.7291(2)?, b=10.9808(2)?, c=36.5334(7)?, ?=?=?=90.00°, Z=8, and a cell volume is 3100.65(11)?3. The content of the chlorogenic acid crystal form in the preparation is 10-5000 mg/g. The preparation is advantageous to bioavailability, and can be used for preparing medicines for treating tumor, psoriasis and other immune system diseases, resisting oxidation, protecting liver and gallbladder, treating cardiovascular diseases, and resisting viruses.Type: GrantFiled: November 18, 2015Date of Patent: June 11, 2019Assignee: SICHUAN JIUZHANG BIOLOGICAL SCIENCE AND TECHNOLOGY CO., LTD.Inventors: Jie Zhang, Lina Zhu, Wang Huang, Liang Zhang
-
Patent number: 10246401Abstract: Provided is a crystalline form of chlorogenic acid. The crystalline form is an orthorhombic crystal system, the space group is P212121, the cell parameters are a=7.7291 (2) ?, b=10.9808 (2) ?, and c=3.5334 (7) ?, ?=?=?=90.00°, Z=8, and the cell volume is 3100.65 (11) ?3. Also provided is a preparation method for the crystalline form. The present crystalline form has good stability and does not significantly change during storage for 48 months in a cool, dark place, and the various indices all meet the relevant requirements for active pharmaceutical ingredients. The crystallization process provided by the present invention can not only use raw materials having different purities to prepare the same crystalline form of chlorogenic acid, but can also significantly reduce solvent residue in the raw materials, thereby improving product safety.Type: GrantFiled: May 16, 2014Date of Patent: April 2, 2019Assignee: SICHUAN JIUZHANG BIOLOGICAL SCIENCE AND TECHNOLOGY CO., LTD.Inventors: Jie Zhang, Liang Zhang, Wang Huang
-
Patent number: 10238702Abstract: The pharmaceutical composition is a formulation prepared by the raw materials in parts by weight: 1-300 parts of chlorogenic acid and 1-50 parts of Ganoderma lucidum spore oil, and the preparative process for said pharmaceutical composition was provided. Chlorogenic acid can be used compatibly with Ganoderma lucidum spore oil, with a synergistic effect. Inclusion technique is applied in product development to improve stability of oily liquid material Ganoderma lucidum spore oil and solid material chlorogenic acid obtained from the extract of Eucommia leaves. After inclusion by the inclusion technology, the liquid drugs become powder, and thus easily oxidized natural products could be protected. Moreover, the damage for active ingredients caused by air can be prevented, and the stability and the taste may get improved.Type: GrantFiled: August 21, 2013Date of Patent: March 26, 2019Assignee: SICHUAN JIUZHANG BIOLOGICAL SCIENCE AND TECHNOLOGY CO., LTD.Inventors: Jie Zhang, Huarong Yang, Chenxu Tian, Lina Zhu, Wang Huang, Yongjiang Yan
-
Patent number: 10189769Abstract: The present invention provides one method for the preparation of pharmaceutically acceptable chlorogenic acid, which comprises the following steps: a. Treating the sample aqueous solution; b. Freezing; c. Thawing and filtering; d. Treating the residue organic phase; e. Concentrating and crystallizing; f. Choosing the number of times to repeat steps a-e according to the variability of chlorogenic acid content in samples; g. Drying. If the chlorogenic acid extract is isolated and purified using this method, water-soluble impurities and liposoluble impurities can be well removed, that allows the impurity content of final products has fulfilled the requirements for medicine; meanwhile, the procedures of this method are simple, and organic solvents can be recycled for further use, with low cost. This method can be applied for the further isolation and purification of chlorogenic acid extract obtained by various ways, especially for the preparation of pharmaceutically acceptable chlorogenic acid.Type: GrantFiled: November 26, 2014Date of Patent: January 29, 2019Assignee: SICHUAN JIUZHANG BIOLOGICAL SCIENCE AND TECHNOLOGY CO., LTD.Inventors: Jie Zhang, Liang Zhang, Wang Huang
-
Patent number: 10058525Abstract: The present invention provides an application of chlorogenic acid in preparing medicines for treating lupus erythematosus. The chlorogenic acid can improve an immunity function. The present invention provides a preparation for treating lupus erythematosus, comprising chlorogenic acid and pharmaceutically acceptable auxiliary materials. The present invention further provides a combined medicine comprising chlorogenic acid and medicines for treating lupus erythematosus.Type: GrantFiled: January 26, 2016Date of Patent: August 28, 2018Assignee: SICHUAN JIUZHANG BIOLOGICAL SCIENCE AND TECHNOLOGY CO., LTD.Inventors: Jie Zhang, Wang Huang, Xiaoguang Chen
-
Patent number: 10004713Abstract: The present invention provides uses of chlorogenic acid in the preparation of medicaments for treatment of oligodendroglioma. Chlorogenic acid according to the present invention has an inhibitory action against oligodendroglioma, and can inhibit the growth of brain tumor stem cells, thus can partly substitute chemoradiation. Chlorogenic acid can alleviate the unwell response of patients caused by chemoradiation, and become a new medicinal therapeutic means and choose for treatment of oligodendroglioma.Type: GrantFiled: October 14, 2014Date of Patent: June 26, 2018Assignee: SICHUAN JIUZHANG BIOLOGICAL SCIENCE AND TECHNOLOGY CO., LTD.Inventors: Jie Zhang, Lina Zhu
-
Patent number: 9918956Abstract: The present invention provides a chlorogenic acid powder-injection. The chlorogenic acid powder-injection is prepared from the following raw materials in parts by weight: 1-120 parts of chlorogenic acid, 1-320 parts of a bracket agent and 1-8 parts of an antioxidant. The present invention further provides a preparation method of the powder-injection. The chlorogenic acid powder-injection provided in the present invention is good in stability, strong in re-solubility and safe in clinical use.Type: GrantFiled: August 21, 2013Date of Patent: March 20, 2018Assignee: SICHUAN JIUZHANG BIOLOGICAL SCIENCE AND TECHNOLOGY CO., LTDInventors: Jie Zhang, Huarong Yang, Chenxu Tian, Yongjiang Yan, Lina Zhu, Wang Huang
-
Patent number: 9884036Abstract: The present invention provides uses of chlorogenic acid in the preparation of medicaments for treatment of psoriasis. Chlorogenic acid, a small molecular compound, is a biological response modifier focusing on the overall regulation, and has a good effect on rebuilding the homeostasis of immune function. Harmful action of chlorogenic acid on liver and kidney is not found, and it can be long-term used, without toxic and side effects on body. Chlorogenic acid is safe and effective, with low recurrence rate, and it can improve life quality of patients. It has an obvious effect on psoriasis, especially on psoriasisvulgaris and psoriasis pustulosa, thus for treatment of psoriasis, chlorogenic acid has a wide application prospects.Type: GrantFiled: September 23, 2014Date of Patent: February 6, 2018Assignee: SICHUAN JIUZHANG BIOLOGICAL SCIENCE AND TECHNOLOGY CO., LTDInventors: Jie Zhang, Lina Zhu
-
Publication number: 20180021395Abstract: Disclosed are a eucommia leaf extract, and preparation method and use thereof. The extract is a liquid of the eucommia leaf or an ethyl alcohol extract, and has chlorogenic acid of a content not less than 9%, geniposidic acid of a content not less than 1% and aucubin of a content not less than 1%. The extract has a good effect on psoriasis.Type: ApplicationFiled: January 30, 2015Publication date: January 25, 2018Applicant: SICHUAN JIUZHANG BIOLOGICAL SCIENCE AND TECHNOLOGY CO., LTD.Inventors: Jie ZHANG, Wang HUANG, Liang ZHANG, Jun HUANG